International Stem Cell Corp (ISCO) financial statements (2021 and earlier)

Company profile

Business Address 5950 PRIESTLY DRIVE
CARLSBAD, CA 92008
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1111001
Cash and cash equivalents1111001
Receivables0111211
Inventory, net of allowances, customer advances and progress billings1111111
Inventory1111111
Other undisclosed current assets0000000
Total current assets:2333333
Noncurrent Assets
Inventory, Noncurrent0000011
Operating lease, right-of-use asset111111 
Property, plant and equipment1111111
Intangible assets, net (including goodwill)1111133
Intangible assets, net (excluding goodwill)1111133
Other undisclosed noncurrent assets0000001
Total noncurrent assets:3333355
TOTAL ASSETS:5677789
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111111
Accounts payable0011111
Accrued liabilities0011111
Debt   000 
Due to related parties 222 22
Other undisclosed current liabilities1110001
Total current liabilities:1444244
Noncurrent Liabilities
Long-term debt and lease obligation111111 
Operating lease, liability111111 
Liabilities, other than long-term debt2   2  
Due to related parties2   2  
Other undisclosed noncurrent liabilities1(0)(0)00 1
Total noncurrent liabilities:4221311
Total liabilities:5565555
Stockholders' equity
Stockholders' equity attributable to parent, including:(4)(4)(4)(3)(3)(1)(1)
Common stock0000000
Additional paid in capital105105104104103103102
Accumulated deficit(109)(108)(108)(107)(106)(104)(104)
Other undisclosed stockholders' equity attributable to parent0000000
Other undisclosed stockholders' equity4444444
Total stockholders' equity:(0)011143
TOTAL LIABILITIES AND EQUITY:5677789

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues1122322
Cost of revenue(1)(1)(1)(1)(1)(1)(1)
Gross profit:1112111
Operating expenses(2)(2)(2)(2)(4)(2)(2)
Operating loss:(1)(1)(1)(0)(2)(1)(1)
Nonoperating income (expense)00(0)0(0)10
Interest and debt expense(0)(0)(0)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(1)(1)(1)(0)(3)(0)(1)
Other undisclosed net income0  00  
Net loss:(1)(1)(1)(0)(3)(0)(1)
Other undisclosed net income attributable to parent 00  00
Net income (loss) available to common stockholders, diluted:(1)(1)(1)(0)(3)0(1)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(1)(1)(1)(0)(3)(0)(1)
Comprehensive loss, net of tax, attributable to parent:(1)(1)(1)(0)(3)(0)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: